Ibogaine for Parkinson's Disease: What Evidence Shows

Parkinson's disease (PD) is a progressive neurodegenerative disorder defined by the loss of dopamine-producing neurons in the substantia nigra, a small region of the midbrain, accompanied by the accumulation of misfolded alpha-synuclein into Lewy bodies. By the time motor symptoms become obvious, a substantial majority of those neurons are already lost.

The classic motor features are bradykinesia (slowness of movement), rigidity, resting tremor, and later postural instability and freezing of gait. Non-motor features often precede diagnosis by years and include constipation, REM sleep behaviour disorder, loss of smell, orthostatic hypotension, depression, anxiety, fatigue, and — in later stages — cognitive impairment and hallucinations.

Scale. The Parkinson's Foundation estimates nearly one million Americans are living with PD, projected to reach 1.2 million by 2030, with roughly 90,000 new US diagnoses each year — about 50% higher than earlier estimates. More than 11 million people are affected worldwide, and a 2025 BMJ modelling study projected over 25 million cases by 2050. Incidence rises steeply with age and is higher in men.

Two facts frame everything that follows.

First, there is no cure and no approved disease-modifying therapy. Every licensed drug treats symptoms; none has been shown to slow the underlying neuron loss.

Second, Parkinson's is notoriously difficult to assess without controls. Symptoms fluctuate hour to hour, progression is slow and variable, and PD produces one of the largest and best-documented placebo responses in clinical medicine — expectation alone can trigger measurable striatal dopamine release. Any uncontrolled report of improvement must be weighed against this.

Parkinson's has genuinely effective symptomatic therapy, supported by decades of randomised evidence. Any experimental option should be judged against it, not against a caricature of it.

• Levodopa/carbidopa remains the most effective drug for motor symptoms and the benchmark against which everything else is measured. Its limitation is well characterised: after roughly five to ten years, most patients develop motor complications — wearing-off, on-off fluctuations, and levodopa-induced dyskinesia
• Dopamine agonists (pramipexole, ropinirole, rotigotine) offer smoother coverage but carry impulse-control disorders, somnolence, and hallucination risk
• MAO-B inhibitors (selegiline, rasagiline, safinamide) and COMT inhibitors (entacapone, opicapone) extend levodopa's effect
• Amantadine is the main option for dyskinesia
• Device-aided therapies for advanced disease include levodopa-carbidopa intestinal gel, subcutaneous foslevodopa and apomorphine infusion

Deep brain stimulation (DBS) has a robust randomised evidence base for reducing off time and dyskinesia and for drug-refractory tremor. Long-term cohort data show off-medication motor scores improved roughly 51% at one year and around 37% still at eight years. MRI-guided focused ultrasound is an option for selected tremor-predominant patients.

Exercise deserves particular emphasis: moderate-to-high-intensity aerobic training is currently the intervention with the most credible claim to modifying disease course, alongside physiotherapy, occupational therapy, and speech therapy for voice and swallowing.

Where conventional care is weakest — and where patient frustration concentrates — is axial symptoms (freezing, falls, postural instability), cognitive decline, and above all the absence of anything that slows neurodegeneration. That gap is what drives interest in experimental options.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied mainly for substance use disorders. Its pharmacology is promiscuous — NMDA antagonism, sigma-2 activity, opioid and nicotinic binding, serotonin transporter effects — and it is metabolised largely by CYP2D6 into noribogaine, a long-lived active metabolite.

Interest in ibogaine for Parkinson's disease rests almost entirely on one mechanism: GDNF.

Glial cell line-derived neurotrophic factor was originally identified as a survival factor for midbrain dopaminergic neurons — precisely the cells lost in PD. This makes Parkinson's the most mechanistically coherent target anyone has proposed for ibogaine outside addiction.

The supporting findings are real but narrow:

• He, Ron and colleagues (Journal of Neuroscience, 2005; FASEB Journal, 2006) showed ibogaine and noribogaine upregulate GDNF through a self-reinforcing autoregulatory loop, producing effects that outlast the drug
• Marton and colleagues (Frontiers in Pharmacology, 2019) found that a single 40 mg/kg dose in rats raised GDNF mRNA roughly 12-fold in the ventral tegmental area and 6-fold in the substantia nigra at 24 hours
• Secondary hypotheses include dopamine transporter modulation and pharmacochaperone activity

The evidence-honest caveats matter:

• These are rodent studies in healthy animals, designed to explain reduced drug and alcohol self-administration — not experiments in a Parkinson's model
• Most measured mRNA, not sustained protein, and over hours to days rather than months
• The 40 mg/kg rodent dose is a flood-dose equivalent. The protocols actually used in Parkinson's patients are roughly one milligram per kilogram per day. Whether that dose induces GDNF at all is unmeasured
• No study of ibogaine in a 6-OHDA, MPTP, or alpha-synuclein Parkinson's model has been published. Work is reportedly underway at Columbia University and, via Ambio, at Dalhousie University with Mitacs funding — but no results have appeared

This is the part most discussion of ibogaine GDNF Parkinson's treatment leaves out, and it is decisive.

GDNF has already been tested in Parkinson's patients — directly, and it did not work.

Because GDNF is a large protein that cannot cross the blood-brain barrier, trials delivered it surgically into the putamen:

• Gill (2003) reported encouraging results in a small open-label study
• Lang (2006), a double-blind phase 2 trial of continuous intraputamenal infusion, failed to show clinical benefit
• Whone (2019, Brain) ran the most rigorous attempt: 41 patients, 120 µg GDNF per putamen every four weeks for 40 weeks via convection-enhanced delivery

The Whone result is worth stating precisely. OFF-state UPDRS motor scores fell 17.3% with GDNF versus 11.8% with placebo — a least-squares mean difference of −4.9%, P = 0.41. The primary endpoint was missed. No secondary motor or quality-of-life endpoint reached significance.

Two findings complicate the picture rather than rescue it. 18F-DOPA PET uptake rose 25–100% across the putamen in the GDNF group only (P < 0.0001) — evidence the drug reached its target — yet PET changes did not correlate with clinical improvement. A post hoc analysis found 43% of active patients versus zero placebo patients achieved a ≥10-point motor improvement (P = 0.0008), which the authors cautioned against over-interpreting.

The investigators themselves raised the possibility that "the underlying growth factor hypothesis is flawed."

So the ibogaine argument requires two unproven links: that oral ibogaine meaningfully raises GDNF in the human brain, and that raising GDNF improves Parkinson's. The second link has negative randomised evidence.

The fair counterargument is that ibogaine could induce GDNF non-invasively and throughout the brain, avoiding the delivery limits that may have doomed the infusion trials. That is a reasonable hypothesis, not a finding.

The peer-reviewed clinical literature on ibogaine for Parkinson's disease consists of one case report describing one patient.

Erny, Cano Montenegro, Barth and Noller published "Ibogaine for the treatment of Parkinson's disease: A case report" in the Journal of Psychedelic Studies in January 2026.

A 52-year-old woman with diminishing response to conventional therapy received titrated daily oral ibogaine hydrochloride, maximum 75 mg/day, over 80 days, assessed with validated instruments — UPDRS, PDQ-39, PDSS-2, PFS-16, BDI-II — plus a qualitative interview.

The authors reported improvement in four of five domains: motor symptoms, quality of life, fatigue, and depression. The patient described reduced freezing-of-gait episodes, better mobility, and increased energy and optimism. Sleep quality declined. No adverse events were recorded.

This is a genuine contribution — the first use of validated PD instruments in this context — and the authors state plainly that larger controlled trials are needed. The limitations are equally plain:

• n = 1. Case reports are hypothesis-generating and cannot establish causation
• No control, no blinding, no randomisation — in a disease with an exceptionally strong placebo response
• Largely subjective endpoints. PDQ-39, PFS-16 and BDI-II are self-reported, UPDRS ratings were not blinded, and no DaTscan, PET, or wearable measure was used
• 80 days is short for any claim about neurodegeneration, and no long-term follow-up is reported

Beyond that, no evidence is peer-reviewed. Ambio Life Sciences soft-launched a neuroregenerative programme in February 2025: roughly 30 patients across Parkinson's, MS, and TBI, using a four-day supervised clinic phase plus six months of at-home microdosing, priced around $6,050. No outcome data has been published.

Brett Favre, diagnosed with Parkinson's in 2024, publicly participated and reported feeling "a real shift, especially in my sleep and energy." A named testimonial carries enormous persuasive weight and essentially no evidentiary weight.

Ibogaine is Schedule I in the United States, so people seeking it travel abroad — most commonly Mexico, also Costa Rica and Portugal. Regulatory oversight varies enormously, and no programme anywhere is an approved Parkinson's treatment.

Two protocol families exist, and the distinction matters:

• Flood dosing (roughly 10–20 mg/kg, single session) is the addiction-derived model, producing many hours of intense psychoactive effect
• Low-dose or microdose regimens are what the Parkinson's literature actually describes — the case report used ≤75 mg/day for 80 days; the Ambio programme combines a short clinic phase with months of at-home dosing

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement and cardiology clearance for any abnormality
• Echocardiogram in higher-risk patients
• Comprehensive metabolic panel with serum potassium and magnesium corrected to normal range before dosing
• Liver and renal function, full blood count
• Full medication reconciliation, screening for QT-prolonging and serotonergic drugs
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure

Parkinson's adds screening that generic protocols omit: supine and standing blood pressure for orthostatic hypotension, a swallow assessment, formal falls-risk evaluation, and cognitive screening, since ibogaine can precipitate confusion and hallucinations in vulnerable patients.

Cardiac telemetry duration deserves scrutiny. Noribogaine's half-life is roughly 28–49 hours, QT prolongation typically persists beyond 24 hours, and adverse cardiac events have been documented 12 to 76 hours after dosing — longer than the monitoring some programmes provide.

Acute effects at meaningful doses include profound ataxia, tremor, nausea, vomiting, and inability to stand unassisted for many hours. For someone already living with gait impairment and possible dysphagia, that compounds fall and aspiration risk. The chronic safety of months of daily low-dose exposure has not been characterised in any published study.

Ibogaine's safety profile is dominated by cardiac electrophysiology, and Parkinson's patients carry compounding risks general protocols rarely address.

The mechanism. Ibogaine and noribogaine block hERG potassium channels — Koenig and Hilber (Molecules, 2015) report IC50 values of roughly 4 µM and 3 µM respectively, concentrations reached at therapeutic doses. Blockade prolongs repolarisation, lengthening the QT interval and raising the risk of torsades de pointes and cardiac arrest.

The magnitude and outcomes. QTc values of 480–700 ms are documented in case reports. Nineteen fatalities between 1990 and 2008 were temporally associated with ibogaine, six from acute cardiac causes. Hypokalaemia was present in every fatality reviewed by Koenig and Hilber; hypomagnesaemia in roughly half.

Why Parkinson's patients are a higher-risk group:

• Cardiac sympathetic denervation is near-universal in PD, and 70–80% of patients have autonomic dysfunction with baroreflex failure. Autonomic instability is itself implicated in ibogaine-associated deaths, and orthostatic hypotension is poorly tolerated alongside vomiting and severe ataxia
• Domperidone, widely used for PD nausea and orthostatic hypotension outside the US, is itself a QT-prolonging drug with a ventricular arrhythmia and sudden-death signal — combining it with a potent hERG blocker is a serious concern
• Antipsychotics for PD psychosis — pimavanserin, quetiapine, clozapine — all prolong QT
• MAO-B inhibitors (selegiline, rasagiline, safinamide) combined with a serotonergically active drug create a theoretical serotonin-toxicity risk. No interaction data with ibogaine exist
• Interrupted levodopa dosing from vomiting or prolonged incapacity can precipitate parkinsonism-hyperpyrexia syndrome, a rare but potentially fatal emergency — an underappreciated, PD-specific danger
• Amantadine and anticholinergics add delirium risk

Preclinical neurotoxicity. O'Hearn and Molliver (Neuroscience, 1993) showed ibogaine degenerates cerebellar Purkinje cells in rats via indirect excitotoxicity through olivocerebellar climbing fibres. Later work placed this at ≥50 mg/kg, with none at 10–40 mg/kg. The risk is dose-dependent, not inevitable — but in a movement disorder, added cerebellar injury would be hard to detect and hard to reverse.

Generally accepted absolute contraindications: long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormality, significant hepatic or renal impairment, pregnancy, and active psychosis.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — no federally accepted medical use — and is not approved for Parkinson's disease anywhere in the world. Texas has committed state funding toward FDA-directed ibogaine trials, but funded trials target opioid use disorder, depression, PTSD, and veterans' brain injury. No Parkinson's trial has been registered.

What would actually advance the question:

• Preclinical work in Parkinson's models. 6-OHDA, MPTP, and alpha-synuclein studies would establish whether ibogaine protects dopaminergic neurons at all
• Pharmacodynamic confirmation. Does the low-dose regimen used in patients raise GDNF in the human brain? Nothing currently demonstrates this, and the rodent data come from far higher doses
• Objective endpoints. Blinded UPDRS raters, DaTscan or 18F-DOPA PET, and wearable kinematic monitoring, rather than self-report questionnaires
• A genuine placebo-controlled trial. Blinding is hard with flood dosing but plausible with sub-perceptual low doses — which makes its absence harder to excuse
• Interaction studies with levodopa, MAO-B inhibitors, and domperidone, and chronic cardiac safety data for months of daily dosing
• A prospective registry, since people are already travelling for treatment

The honest bottom line. The case for ibogaine for Parkinson's disease rests on one published patient, rodent neurotrophic findings at doses far above those used clinically, and a growth-factor hypothesis that failed when tested directly in randomised trials. Set against that is a documented, potentially fatal cardiac risk that intersects badly with Parkinson's autonomic pathology and medication list.

This is a question worth researching. It is not a question that has been answered.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about Parkinson's treatment should be made with a treating neurologist. Never stop or interrupt levodopa or other PD medication without medical supervision — abrupt withdrawal can be dangerous.